Press release

January 28, 2016

Aragen Bioscience Announces Ground Breaking on State Of the Art Research Facility

MORGAN HILL, California – January 28, 2016: Aragen Bioscience, Inc. (Aragen), leading contract research organization specializing in the study and early development of biologic and diagnostic products, has initiated construction on a new, state of the art research facility. Dedicated to the testing and characterization of novel therapeutics and vaccines, the new research space will add 15,000 sq.ft. to Aragen’s existing laboratories and will double capacity for diverse efficacy studies. Such studies are critical to the development of products that improve the diagnosis, treatment and prevention of disease including for example, fibrotic and infectious disease, oncology and other immunologically related indications.

“This project demonstrates Aragen’s commitment to future growth and meeting the needs of our clients for value-added services. The new facility not only expands general capacity but is constructed for high technical performance and tight environmental control including provision of BSL-2 studies. We look forward to seeing the building progress and its opening later this year,” commented Dr. Malavika Ghosh, Aragen’s Vice President of Preclinical Services.

The facility, which is designed for AAALAC accreditation and GLP compliance, is scheduled to be functional in the second quarter of 2016.

For more information please visit


Oren Beske, Ph.D., Aragen Bioscience
Phone: +1 408 779 1700

Sarah Jeffery, Zyme Communications
Phone: +44 (0)7771 730919

About Aragen Bioscience

Aragen Bioscience, Inc. (Aragen, Morgan Hill, CA, USA) is a privately held contract research organization with offices and laboratories in the San Francisco Bay Area. Aragen Bioscience offers a diverse set of in vitro and in vivo services for the discovery, characterization, activity assessment and early development of biologic and diagnostic products. More information on Aragen Bioscience, Inc. can be found at